Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) EPS (Basic): 2009-2025

Historic EPS (Basic) for China Pharma Holdings (CPHI) over the last 17 years, with Sep 2025 value amounting to -$0.17.

  • China Pharma Holdings' EPS (Basic) rose 73.85% to -$0.17 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.41, marking a year-over-year increase of 161.84%. This contributed to the annual value of -$0.27 for FY2024, which is 70.33% up from last year.
  • As of Q3 2025, China Pharma Holdings' EPS (Basic) stood at -$0.17, which was down 6.25% from -$0.16 recorded in Q2 2025.
  • In the past 5 years, China Pharma Holdings' EPS (Basic) registered a high of $1.98 during Q4 2024, and its lowest value of -$3.22 during Q4 2022.
  • In the last 3 years, China Pharma Holdings' EPS (Basic) had a median value of -$0.29 in 2023 and averaged -$0.16.
  • In the last 5 years, China Pharma Holdings' EPS (Basic) tumbled by 2,200.00% in 2021 and then spiked by 10,000.00% in 2024.
  • Over the past 5 years, China Pharma Holdings' EPS (Basic) (Quarterly) stood at -$0.69 in 2021, then crashed by 366.67% to -$3.22 in 2022, then skyrocketed by 99.38% to -$0.02 in 2023, then skyrocketed by 10,000.00% to $1.98 in 2024, then surged by 73.85% to -$0.17 in 2025.
  • Its EPS (Basic) stands at -$0.17 for Q3 2025, versus -$0.16 for Q2 2025 and -$0.24 for Q1 2025.